MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative, next-generation antibody-based therapies to improve the lives of cancer patients. The Company is advancing a broad pipeline of novel product candidates incorporating proprietary technology platforms for antibody-drug conjugates (ADCs), bispecific checkpoint antibodies, and next-generation T-cell engagers. MacroGenics has developed three FDA-approved therapies and has entered into strategic collaborations with companies such as Incyte, Gilead and Sanofi.